Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3598
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$35.22
Market Cap
$4.73B
Change (1 day)
6.82%
Change (1 year)
222.07%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
Stock split history for Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. stock (symbol: DFTX) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One DFTX share bought prior to Oct 20, 2026 would equal to 0 DFTX shares today.
The most recent stock split occurred on Oct 20, 2026.
One DFTX share bought prior to Oct 20, 2026 would equal to 0 DFTX shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
